Skip to content

KLRS KLRS Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Regenxbio logo
RegenxbioRGNX
PVL
Palvella TherapeuticsPVLA

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's accrued expenses and other liabilities?
KLRS (KLRS) reported accrued expenses and other liabilities of $120K in Q1 2026.
How has KLRS's accrued expenses and other liabilities changed year-over-year?
KLRS's accrued expenses and other liabilities increased by 1600.0% year-over-year, from -$8K to $120K.